ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2025
[Clincial Diagnostic Performance of EULAR/ACR-2019, SLICC-2012, and ACR-1997 Classification Criteria for Childhood Systemic Lupus Erythematosus].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Clinical Manifestations of Childhood Systemic Lupus Erythematosus-associated Acute Pancreatitis and Evaluation of the Efficacy of Plasma Exchange Combined With Glucocorticoids].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic performance of the 1997 American College of Rheumatology (ACR) criteria, the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria, and the 2019 European League Against Rheumatism (EULAR)/ACR criteria for childhood systemic lupus erythematosus (cSLE) in Southwest China. Methods: A retrospective analysis was conducted with 264 cSLE patients and 237 non-cSLE patients with connective tissue disease receiving treatment at West China Second University Hospital, Sichuan University between January 2013 and December 2022. The sensitivity, specificity, positive/negative predictive values, and accuracy of the three classification criteria were compared. Stratified analyses by sex and age were performed to comprehensively assess the diagnostic performance of the three classification criteria. Furthermore, receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cut-off value for maximizing the sensitivity of the EULAR/ACR-2019 criteria. Results: The SLICC-2012 criteria demonstrated higher sensitivity (93.9% vs. 76.5% vs. 90.2%) and accuracy (95.4% vs. 87.4% vs. 93.8%) compared to the ACR-1997 and EULAR/ACR-2019 criteria, while the ACR-1997 criteria showed the highest specificity (99.5%). Stratified analysis revealed stable sensitivity (94%-96%) for the SLICC-2012 criteria across sex and prepubertal subgroups. Removing the entry criterion of antinuclear antibody (ANA) ≥ 1∶80 or adjusting the total score cut-off value to ≥ 13 (original score > 10) improved the sensitivity of the EULAR/ACR-2019 criteria. Conclusion: The SLICC-2012 criteria exhibited optimal diagnostic performance for cSLE in Southwest China. Modifying the cut-off value and entry requirements of the EULAR/ACR-2019 criteria could enhance its applicability in pediatric populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.